Progress with Chronic Myelogenous Leukemia: A Personal Perspective over Four Decades

Literature Cited

1. Nowell PC. 1993. From chromosomes to oncogenes: a personal perspective. In The Causes and Consequences of Chromosomal Aberrations, ed. IR Kirsch 505–16 Boca Raton, FL: CRC
2. Osgood EE, Krippaehne ML. 1955. The gradient tissue culture method.. Exp. Cell Res. 9:116–27 [Google Scholar]
3. Nowell P, Cole L, Ellis M. 1956. Induction of intestinal carcinoma in the mouse by whole-body fast neutron irradiation.. Cancer Res. 16:873–76 [Google Scholar]
4. Tjio JM, Levan A. 1956. The chromosome number of man.. Hereditas 42:1–6 [Google Scholar]
5. Nowell P, Hungerford D, Brooks C. 1958. Chromosomal characteristics of normal and leukemic human leukocytes after short-term tissue culture.. Proc. Am. Assoc. Cancer Res. 2:331 [Google Scholar]
6. Nowell P, Hungerford D. 1960. Chromosomes of normal and leukemic human leukocytes.. J. Natl. Cancer Inst. 25:85–109 [Google Scholar]
7. Nowell P, Hungerford D. 1960. A minute chromosome in human chronic granulocytic leukemia.. Science 132:1497 [Google Scholar]
8. Tough IM, Court Brown WM, Baikie AG. et al. 1961. Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with mongolism.. Lancet 1:411–17 [Google Scholar]
9. Hsu TC. 1979. Human and Mammalian Cytognetics. New York: Springer-Verlag [Google Scholar]
10. Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining.. Nature 243:290–93 [Google Scholar]
11. Heim S, Mitelman F. 1987. Cancer Cytogenetics. New York: Liss [Google Scholar]
12. Cole L, Nowell P. 1965. Radiation carcinogenesis: the sequence of events.. Science 150:1782–86 [Google Scholar]
13. Rowley JD. 1980. Ph-positive leukaemia, including chronic myelogenous leukaemia.. Clin. Haematol. 9:55–86 [Google Scholar]
14. Nowell P. 1976. The clonal evolution of tumor cell populations.. Science 194:23–28 [Google Scholar]
15. Groffen J, Stephenson JR, Heisterkamp N. et al. 1984. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.. Cell 36:93–99 [Google Scholar]
16. Fialkow FJ, Denman AM, Jacobson RJ. et al. 1978. Chronic myelocytic leukemia: origin of some lymphocytes from leukemic stem cells.. J. Clin. Invest. 62:815–20 [Google Scholar]
17. Nitta M, Kato Y, Strife A. et al. 1985. Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia.. Blood 66:1053–59 [Google Scholar]
18. Nowell PC, Finan JB, Moore JS. et al. 1989. Ph-negative T cells in a patient with chronic myelogenous leukemia for twenty-eight years.. Leuk. Res. 13:1019–23 [Google Scholar]
19. Kurzrock R, Shtarid M, Romero P. et al. 1987. A novel c-Abl protein product in Philadelphia-positive acute lymphoblastic leukaemia.. Nature 325:631–35 [Google Scholar]
20. Chan LC, Karhi KK, Rayter SI. et al. 1987. A novel Abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia.. Nature 325:635–37 [Google Scholar]
21. Feinstein E, Cimino G, Gale RP. et al. 1991. p53 in chronic myelogenous leukemia in acute phase.. Proc. Natl. Acad. Sci. USA 88:6293–97 [Google Scholar]
22. Nakai H, Misawa S. 1995. Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance.. Leuk. Lymphoma 19:213–18 [Google Scholar]
23. Nowell PC, Croce CM. 1990. Chromosome translocations and oncogenes in human lymphoid tumors.. Am. J. Clin. Pathol. 94:229–37 [Google Scholar]
24. Tsujimoto Y, Finger L, Yunis J. et al. 1984. Cloning of the chromosome breakpoint of neoplastic B-cells with the t(14;18) chromosome translocation.. Science 226:1097–99 [Google Scholar]
25. Hockenbury D, Nuñez G, Milliman C. et al. 1990. Nature 348:334–36
26. Lugo TG, Pendergast A-M, Muller AJ. et al. 1990. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products.. Science 247:1079–82 [Google Scholar]
27. Sawyers CL, McLaughlin J, Witte ON. 1995. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the BCR-ABL oncogene.. J. Exp. Med. 181:307–13 [Google Scholar]
28. Odai H, Sasaki K, Iwamatsu A. et al. 1997. Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.. Blood 89:2745–56 [Google Scholar]
29. Shuai K, Halpern J, ten Hoeve J. et al. 1996. Constitutive activation of STATS by the BCR-ABL oncogene in chronic myelogenous leukemia.. Oncogene 13:247–54 [Google Scholar]
30. Sanchez-Garcia I, Grutz G. 1995. Tumorigenic activity of the BCR-ABL oncogene is mediated by BCL2.. Proc. Natl. Acad. Sci. USA 92:5287–91 [Google Scholar]
31. Verfaillie CM, Hurley R, Lundell BI. et al. 1997. Integrin-mediated regulation of hematopoiesis: Do Bcr/Abl-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?. Acta Haematol. 97:40–52 [Google Scholar]
32. Takeda N, Shibuya M, Maru Y. 1999. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.. Proc. Natl. Acad. Sci. USA 96:203–7 [Google Scholar]
33. Fialkow PJ, Martin PJ, Najfeld V. et al. 1981. Evidence for a multistep pathogenesis of chronic myelogenous leukemia.. Blood 58:158–63 [Google Scholar]
34. Nowell PC, Moreau L, Growney P. et al. 1988. Karyotypic stability in chronic B cell leukemia.. Cancer Genet. Cytogenet. 33:155–60 [Google Scholar]
35. Cunningham I, Gee T, Dowling M. et al. 1979. Results of treatment of Ph-positive chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).. Blood 53:375–95 [Google Scholar]
36. Faderl S, Talpaz M, Estrov Z. et al. 1999. Chronic myelogenous leukemia: biology and therapy.. Ann. Int. Med. 131:207–19 [Google Scholar]
37. Silver RT, Woolf SH, Hehlmann R. et al. 1999. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.. Blood 94:1517–36 [Google Scholar]
38. Nowell P, Cole L, Habermeyer J. et al. 1956. Growth and continued function of rat marrow cells in X-irradiated mice.. Cancer Res. 16:258–61 [Google Scholar]
39. Apperly JF. 1998. Hematopoietic stem cell transplantation in chronic myeloid leukemia.. Curr. Opin. Hematol. 5:445–53 [Google Scholar]
40. Porter DL, Antin JH. 1999. The graft-versus-leukemia effects of allogeneic cell therapy.. Annu. Rev. Med. 50:369–86 [Google Scholar]
41. Kronenwett R, Haas R. 1998. Specific BCR-ABL-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?. Recent Results Cancer Res. 144:127–38 [Google Scholar]
42. Gewirtz AM, Sokol DL, Ratajczak MZ. 1998. Nucleic acid therapeutics: state of the art and future prospects.. Blood 92:712–36 [Google Scholar]
43. Luger S, O'Brien S, Ratajczak M. et al. 2000. Bone marrow purging with c-myb targeted oligodeoxynucleotides: results and long-term follow-up of a pilot study in CML patients.. Blood 96:A609a [Google Scholar]
44. Cuneo A, Bigoni R, Emmanuel B. et al. 1998. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis.. Leukemia 12:1718–23 [Google Scholar]
45. Chomel J-C, Brizard F, Veinstein A. et al. 2000. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogeneic bone marrow transplantation.. Blood 95:404–9 [Google Scholar]
46. Stryckmans P, Biernaux C, Sels A. et al. 1995. Very low levels of major BCR-ABL expression in blood of some healthy individuals.. Blood 86:3118–22 [Google Scholar]
47. Druker BJ, Tamura S, Buchdunger E. et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.. Nat. Med. 2:561–66 [Google Scholar]
48. Druker BJ, Talpaz M, Resta D. et al. 1999. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia.. Blood 94(10):A1639 [Google Scholar]
49. Weisberg E, Griffin JD. 2000. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.. Blood 95:3498–3505 [Google Scholar]